Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant carboplatin + paclitaxel for metastatic vulvar squamous cell carcinoma
NL-OMON49490Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in vulvar squamous cell carcinoma (VSCC), sponsored by Netherlands Cancer Institute. Primary endpoints: Response rate and Tumor size reduction. Started May 2020; status: recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NL-OMON49490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49490.